Larimar Therapeutics: A Resilient Rise After FDA Removal of Clinical Hold
The Triumph of Larimar Therapeutics Amid FDA Regulatory Shift
Iryna Drozd Larimar Therapeutics’ stock, listed under NASDAQ as LRMR, soared by an impressive 24% during after-hours trading on Monday. This surge was triggered by the exhilarating news that the FDA had lifted a partial clinical hold on Larimar’s nomlabofusp clinical program following a meticulous assessment of Phase 2 data pertaining to the drug. Among ...












